Literature DB >> 16452829

Fat paradox in liver disease.

Hide Tsukamoto1.   

Abstract

Alcoholic liver disease (ALD) is characterized by accumulation of neutral lipids in hepatocytes leading to micro and macro-vesicular steatosis and balloon cell degeneration. Hypercaloric alimentation and resultant obesity also cause similar changes as evident in non-alcoholic fatty liver disease (NAFLD). Thus, accumulation of lipids in hepatocytes is a pathologic hallmark of ALD and NAFLD. In contrast, quiescent hepatic stellate cells (HSC) are characterized by the intracellular content of not only vitamin A but also triglycerides, and HSC activation is associated with depletion of these lipids. In fact, our recent work demonstrates that adipogenic/ lipogenic transcriptional regulation rendered by PPARgamma, LXRa, and SREBP-1c is essential for the maintenance of the fat-storing, quiescence phenotype of HSC. Expression of these adipogenic transcription factors is lost in activated HSC and the treatment of the cells with the adipocyte differentiation cocktail or ectopic expression of PPARgamma or SREBP-1c causes a reversal of activated cells to the quiescent phenotype. In steatotic livers from ALD and NAFLD mouse models, the expression of these adipogenic transcription factors is induced while the normal control livers lack such expression. Thus, adipogenic regulation is essential for HSC quiescence while it makes hepatocytes steatotic. Interestingly, under the adipogenic conditions of ALD and NAFLD, HSC are still activated to cause fibrosis. This fat paradox in hepatocytes and HSC highlights contrasted significance of fat in these two cell types that depend on each other for their homeostatic control. It further suggests, activated HSC in steatotic livers may have defective insulin signaling or lipogenic regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16452829     DOI: 10.2302/kjm.54.190

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  17 in total

1.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

2.  PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

Authors:  Caiyan Zhao; Wei Chen; Liu Yang; Lihong Chen; Stephen A Stimpson; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

Review 3.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 4.  Lipotoxicity in the liver.

Authors:  Veronika Zámbó; Laura Simon-Szabó; Péter Szelényi; Eva Kereszturi; Gábor Bánhegyi; Miklós Csala
Journal:  World J Hepatol       Date:  2013-10-27

5.  Resveratrol increases the activation markers and changes the release of inflammatory cytokines of hepatic stellate cells.

Authors:  Cleverson Moraes de Oliveira; Leo Anderson Meira Martins; Arieli Cruz de Sousa; Ketlen da Silveira Moraes; Bruna Pasqualotto Costa; Moema Queiroz Vieira; Bárbara Paranhos Coelho; Radovan Borojevic; Jarbas Rodrigues de Oliveira; Fátima Costa Rodrigues Guma
Journal:  Mol Cell Biochem       Date:  2020-10-19       Impact factor: 3.396

6.  Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.

Authors:  Xiao Liu; Jun Xu; David A Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2013-09

Review 7.  Bone marrow-derived fibrocytes contribute to liver fibrosis.

Authors:  Jun Xu; Tatiana Kisseleva
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

8.  Pathophysiological characteristics of dimethylnitrosamine-induced liver fibrosis in acute and chronic injury models: a possible contribution of KLF5 to fibrogenic responses.

Authors:  Fumihiro Ohara; Aisuke Nii; Yojiro Sakiyama; Megumi Tsuchiya; Shinji Ogawa
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

9.  Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease.

Authors:  Anping Chen; Youcai Tang; Victoria Davis; Fong-Fu Hsu; Susan M Kennedy; Haowei Song; John Turk; Elizabeth M Brunt; Elizabeth P Newberry; Nicholas O Davidson
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

10.  Curcumin adds spice to the debate: lipid metabolism in liver disease.

Authors:  Annette Graham
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.